Proceeds support advancing leading pre-clinical development candidate BT-267, a best-in-class leucine-rich repeat kinase 2 (LRRK2) inhibitor, into human clinical trials for the treatment of idiopathic and LRRK2-mutuated Parkinson's disease

收益支持将领先的临床前开发候选物BT-267（一种一流的富含亮氨酸的重复激酶2（LRRK2）抑制剂）推进人类临床试验，以治疗特发性和LRRK2突变型帕金森病

Additional assets targeting Parkinson's disease will also be evaluated and potentially added to fuel the neurology-focused pipeline

还将评估针对帕金森氏病的其他资产，并可能增加这些资产，以推动以神经病学为重点的管道

DOVER, Del., July 23, 2024 /PRNewswire/ -- Brenig Therapeutics Inc. (Brenig), a pioneering neurology-focused drug development company utilizing an AI/ML-based discovery platform, today announced the closing of a $65 million Series A financing. The financing was led by New Enterprise Associates (NEA) with support from an additional US-based healthcare investor as well as existing investors: OrbiMed, Torrey Pines Investments and BioGeneration Ventures.

多佛，Del。，2024年7月23日/PRNewswire/--Brenig Therapeutics Inc.（Brenig），一家开创性的神经病学药物开发公司，利用基于AI/ML的发现平台，今天宣布关闭6500万美元的a系列融资。此次融资由新企业联合会（NEA）牵头，并得到了另一位美国医疗保健投资者以及现有投资者的支持：OrbiMed、TorreyPines Investments和BioGeneration Ventures。

In connection with the financing, Ed Mathers, Partner at NEA, will join the Board of Directors..

在融资方面，NEA合伙人Ed Mathers将加入董事会。

'With the financing, we advance our goal of addressing the needs of Parkinson's disease patients with our differentiated drugs,' commented Iain Dukes MA DPhil, Chairman of Brenig.

Brenig董事长伊恩·杜克斯·马德希尔（IainDukes MA DPhil）评论道：“通过资金支持，我们推进了用我们的差异化药物满足帕金森病患者需求的目标。”

'The Brenig team has made remarkable progress since inception,' said Ed Mathers. 'We believe their approach could lead to best-in-class therapeutics for the treatment of Parkinson's disease. NEA is thrilled to partner with Brenig through its next phase of growth'.

埃德·马瑟斯（EdMathers）说，布雷尼格团队自成立以来取得了显著进展我们相信他们的方法可以为帕金森病的治疗带来一流的治疗方法。NEA很高兴能与Brenig合作完成下一阶段的增长”。

Brenig plans to use the proceeds from this financing to advance BT-267 through healthy volunteer studies and into proof-of-concept studies in idiopathic Parkinson's disease patients. In addition, the company will explore advancing additional best-in-class approaches for Parkinson's disease.

Brenig计划将这笔资金的收益用于通过健康志愿者研究推进BT-267，并用于特发性帕金森病患者的概念验证研究。此外，该公司将探索推进帕金森病的其他同类最佳方法。

BT-267, a small molecule LRKK2 inhibitor, was designed to have a best-in-class PK profile enabling high and sustained brain exposure and minimal peripheral exposure, thereby ensuring superior efficacy while minimizing on-target, off-tissue toxicity. The molecule exhibits exquisite kinome selectivity, avoiding off-target effects.

BT-267是一种小分子LRKK2抑制剂，被设计为具有最佳的PK谱，能够实现高持续的大脑暴露和最小的外周暴露，从而确保优异的疗效，同时最大程度地减少靶向，非组织毒性。该分子表现出精细的激酶选择性，避免了脱靶效应。

A clean safety profile has been confirmed through ongoing GLP studies..

通过正在进行的GLP研究已经证实了清洁的安全性。

About Brenig Therapeutics

关于Brenig Therapeutics

Brenig is a small molecule drug development company that utilizes an AI/ML approach via a partnership with Expert Systems Inc., a drug accelerator that has spawned multiple best-in-class clinical candidates across multiple therapeutic areas.

Brenig是一家小分子药物开发公司，通过与Expert Systems Inc.的合作，利用AI/ML方法，Expert Systems Inc.是一家药物加速器，在多个治疗领域产生了多个一流的临床候选人。

About NEA

关于NEA

New Enterprise Associates, Inc. (NEA) is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors, and geographies. Founded in 1977, NEA has over $25 billion in assets under management as of December 31, 2023, and invests in technology and healthcare companies at all stages in a company's lifecycle, from seed stage through IPO.

New Enterprise Associates，Inc.（NEA）是一家全球风险投资公司，专注于帮助企业家在多个阶段、部门和地区建立转型型企业。

The firm's long track record of investing includes more than 270 portfolio company IPOs and more than 450 mergers and acquisitions. For more information, please visit www.nea.com..

该公司的长期投资记录包括270多家投资组合公司的首次公开募股和450多宗并购。欲了解更多信息，请访问www.nea.com。

Media Contact:

媒体联系人：

Iain Dukes, PhDExecutive Chairmandukesi@orbimed.com

Iain Dukes博士Chairmandukesi@orbimed.com

SOURCE Brenig Therapeutics

来源Brenig Therapeutics